Rare Diseases

A successful incentive compensation (IC) program requires a robust sales crediting process. The timely availability of data in a suitable structured format is essential for critical ...

In recent years, rare disease products, or orphan drugs, have observed an increase in research and development (R&D) focus from pharma, biopharma, and biotech companies. A study ...

There are multiple challenges for the development, approval, and commercialization of any novel therapy, especially in a niche rare disease landscape. To mitigate these challenges in the ...

Problem Rare diseases, also known as orphan diseases, affect a small percentage of the patient population (<200,000 patients in the US but usually much lower) with much higher drug ...

The United States Food and Drug Administration (FDA) defines a rare disease or orphan disease as a disease or state that affects less than 200,000 patients in the US, or that affects no ...

The world of health and medicine has broken countless barriers over the last few scores. Life sciences companies have continued to invest significantly in their research of globally ...

As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence ...

As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence ...

At the PMSA annual conference, Axtria’s Sudeep Saha and Celgene’s Jennifer Maurer shared an approach that demonstrated how to use patient-level data in a robust way to estimate market ...